Replies to post #333778 on Amarin Corp Plc (AMRN)

[Bouf]

CB—

Correct, very troubling the biggest or one of biggest insurers does this. This shows the strength of the headwinds faced by the company irrespective of litigation over the patents.

Can anyone with more industry experience explain how the company could allow this to happen?

Will other Insurers follow?

B

[zmanindc]

I get the idea they want to maximize profit but that doesn’t work if they are covering GL over V. First, I don’t think GL is that much cheaper than V but every paid bottle is just a waste of money. They will not get the benefit of the ROI with the reduction in CV events. Just a waste of money and hurts UHC subscribers.

[Meowza]

significantly cheaper

How? Aneurysms and infarctions are expensive.

[Number sleven]

Could, They can not switch a prescription for Vascepa to generic lavaza. These two drugs are not equivalent. It would be the same as substituting aspirin for a prescription for crestor.
Sleven,